The rise of immuno-oncology in China: a challenge to western dominance?

Mark P. Lythgoe; Grant Lewison; Ajay Aggarwal; Chris Booth; Mark Lawler; Dario Trapani; Manju Sengar; Richard Sullivan

doi:10.1016/S1470-2045(23)00026-8

The rise of immuno-oncology in China: a challenge to western dominance?

Mark P. Lythgoe^*, Grant Lewison, Ajay Aggarwal, Chris Booth, Mark Lawler, Dario Trapani, Manju Sengar, Richard Sullivan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	439-441
Number of pages	3
Journal	Lancet Oncology
Volume	24
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(23)00026-8
Publication status	Published - May 2023

Keywords

Neoplasms - epidemiology - therapy
Immunotherapy - adverse effects
Medical Oncology
China - epidemiology
Humans

Access to Document

10.1016/S1470-2045(23)00026-8Licence: Unspecified

Cite this

@article{117486fb425249db89ce709309fe29f7,

title = "The rise of immuno-oncology in China: a challenge to western dominance?",

keywords = "Neoplasms - epidemiology - therapy, Immunotherapy - adverse effects, Medical Oncology, China - epidemiology, Humans",

author = "Lythgoe, {Mark P.} and Grant Lewison and Ajay Aggarwal and Chris Booth and Mark Lawler and Dario Trapani and Manju Sengar and Richard Sullivan",

year = "2023",

month = may,

doi = "10.1016/S1470-2045(23)00026-8",

language = "English",

volume = "24",

pages = "439--441",

journal = "Lancet Oncology",

issn = "1474-5488",